Daily mindfulness practice with and without slow breathing has opposing effects on plasma amyloid beta levels

Kaoru Nashiro[1], B. Rael Cahn[1], Paul Choi[1], Hye Rynn J. Lee[1], Shaakhini Satchi[1], Jungwon Min[1], Hyun Joo Yoo[1], Christine Cho[1], Noah Mercer[1], Lorena Sordo[2], Elizabeth Head[2], Jeiran Choupan[1] and Mara Mather[1]*

[1]University of Southern California, [2]University of California, Irvine

Kaoru Nashiro, Ph.D.
Research Associate Professor
Leonard Davis School of Gerontology
University of Southern California
nashiro@usc.edu

Baruch Rael Cahn, MD, PhD
Clinical Associate Professor
Psychiatry and the Behavioral Sciences
University of Southern California
rael.cahn@usc.edu

Paul Choi
Project Assistant
Leonard Davis School of Gerontology
University of Southern California
choipaul@usc.edu

Hye Rynn J. Lee
Project Assistant
Leonard Davis School of Gerontology
University of Southern California
hjlee@usc.edu

Shaakhini Satchi
Research Assistant
Leonard Davis School of Gerontology
University of Southern California
ssatchi@usc.edu

Jungwon Min, Ph.D.
Postdoctoral Scientist
Leonard Davis School of Gerontology
University of Southern California
minjungw@usc.edu

Hyun Joo Yoo, Ph.D.
Research Scientist
Leonard Davis School of Gerontology
University of Southern California

hyunjooy@usc.edu

Noah Mercer
Software Consultant
University of Southern California
noahmerc@usc.edu

Christine Cho
Project Manager
Leonard Davis School of Gerontology
University of Southern California
cho890@usc.edu

Lorena Sordo, Ph.D.
Postdoctoral Scientist
Department of Pathology & Laboratory
Medicine
University of California, Irvine
lsordo@hs.uci.edu

Elizabeth Head, Ph.D.
Professor
Department of Pathology & Laboratory
Medicine
University of California, Irvine
heade@uci.edu

Jeiran Choupan, Ph.D.
Assistant Professor of Research Neurology
Keck School of Medicine
University of Southern California
NeuroScope Inc.
choupan@usc.edu

Mara Mather, Ph.D.
Professor
Leonard Davis School of Gerontology
University of Southern California
mara.mather@usc.edu

Abstract

Prior research suggests that meditation may slow brain aging and reduce the risk of Alzheimer's disease (AD). However, we lack research systematically examining what aspect(s) of meditation may drive such benefits. In particular, it is unknown how breathing patterns during meditation might influence health outcomes associated with AD. In this study, we examined whether two types of mindfulness meditation practices - one with slow breathing and one with normal breathing – differently affect plasma amyloid beta (Aβ) relative to a no-intervention control group. One week of daily mindfulness practice with slow breathing decreased plasma Aβ levels whereas one week of daily mindfulness practice with normal breathing increased them. The no-intervention control group showed no changes in plasma Aβ levels. Slow breathing appears to be a factor through which meditative practices can influence pathways relevant for AD.

Meditative practices have been shown to be associated with slowing brain aging[1–6] and may help reduce the risk of or delay the onset of Alzheimer's disease (AD)[7–10]. However, little is known about what mechanisms might lead meditation to have such benefits. While most prior studies focus on how meditative practices benefit health via mental training aspects (e.g., paying attention to the present moment)[9,11,12] or by promoting relaxation and rest[13], the effects of different breathing patterns during meditative practices on health have been relatively little explored. Meditative practices tend to affect breathing and breath rate[14–16], which can elicit powerful physiological effects that might influence AD-related health outcomes.

Separately from meditation per se, slow breathing around the baroreflex frequency (6 breath per minute, 0.1 Hz, or 10 s/breath) generally activates parasympathetic vagus nerve activity, suppresses sympathetic/noradrenergic activity, and increases heart rate oscillations[17,18]. Repeated practice of baroreflex-frequency breathing to increase heart rate oscillations promotes a number of health benefits, including long-term emotional health[17] and positive effects on cardiovascular diseases[19]. During some meditative practices, breathing has been shown to slow, thus driving large heart rate oscillations at the breathing frequency[20–22]. For example, an expert meditator focusing on the breath during a Samadhi meditation showed high amplitude heart rate oscillations around 0.1 Hz[23], indicating that breathing slowed to around the baroreflex frequency during meditation. Similar increases in heart rate oscillations have been observed in Qigong, Kundalini yoga, or Zazen practitioners[21,22,24] or in people reciting either the rosary or a typical yoga mantra[20]. Tai Chi also increases abdominal breathing and heart rate oscillatory activity[25]. However, not all meditative practices increase heart rate oscillations. For instance, in one study, the Vipassana Anapana practice as taught by S.N. Goenka, involving specific concentration on the minute sensations around the nostrils and the upper lip, does not increase high and low

frequency HRV in long term daily practitioners[26]. A recent systematic review[15] found that of the five studies they found that assessed respiratory rate during meditation compared with baseline in long-term meditators, three studies (with Vipassana meditators doing a breath awareness practice[27], Raja Yoga meditators during their practice[28] and transcendental meditation practitioners during their practice[29]) documented slower breathing during meditation practice than during baseline. Two other studies with long-term meditators doing an "OM" meditation[30,31] showed no changes in respiratory rate during their practice compared with baseline. Given the known health benefits of slow breathing especially around the baroreflex frequency, it is possible that meditative practices with or without slow breathing may lead to different types of health benefits, a hypothesis the current study set out to explore.

In our recent clinical trial (the Heart Rate Variability and Emotion Regulation or HRV-ER)[32], we found that randomizing participants to four weeks of daily practice of baroreflex frequency breathing reduced their plasma amyloid beta (Aβ) levels, levels of which are associated with increased risk for AD[33], in both healthy younger and older adults (aged 18-35 and 55-80, respectively). In contrast, participants who were randomized to an active comparison group without slow paced breathing showed increases in plasma Aβ. We hypothesized that baroreflex frequency breathing decreases overall Aβ levels by decreasing Aβ production. Aβ is generated by two sequential cleavages of amyloid precursor protein (APP) by β and γ secretase (amyloidogenic pathway; right side of Fig. 1)[34]. However, if APP is first cleaved by α secretase rather than by β secretase, no Aβ is produced (nonamyloidogenic pathway; left side of Fig. 1). Cholinergic M1 and M3 receptors activate the α-secretase APP nonamyloidogenic pathway and suppress the β-secretase amyloidogenic pathway. Thus, it seems plausible that the baroreflex frequency breathing, which stimulates parasympathetic activity, concurrently promotes the

nonamyloidogenic pathway, possibly through cholinergic M1 and M3 receptors, leading to a

reduction of Aβ production. In contrast, noradrenergic receptor activity can bias APP cleavage

towards the amyloidogenic pathway[35,36]. It is possible that the HRV-ER active control involving

a meditative state while attending to heart rate biofeedback increased noradrenergic activity by

focusing attention, and that noradrenergic activity biased APP processing to increase Aβ

production.

Figure 1. Cholinergic and noradrenergic activity bias the cleavage of amyloid precursor
protein (APP) to produce Aβ or not.

Image adapted from Chen et al. (2017).

According to the amyloid hypothesis[37,38], an imbalance between Aβ production and

clearance initiates a cascade of events leading to progression of AD. Consistent with this

hypothesis, Aβ42 levels in CSF start to increase in early adulthood and peak in middle adulthood[39]. Plasma Aβ40 and Aβ42 levels are elevated in people with genetic risk of AD before onset of disease symptoms[40–45]. Consistent with these higher plasma Aβ levels in at-risk individuals, a meta-analysis of longitudinal studies indicates that higher baseline Aβ40 and Aβ42 levels in cognitively normal individuals predict conversion to AD[33].

While plasma Aβ levels are elevated during pre-symptomatic stages in older and other at-risk individuals, plasma Aβ42 levels decrease around the time of an AD diagnosis[33]. This results in decreased Aβ42 to Aβ40 ratios. High precision assays of plasma Aβ42/Aβ40 ratios correspond with amyloid PET (AUC 0.94)[33,46,47]. Aβ42 is more likely than Aβ40 to form aggregates in the brain[48]; therefore, Aβ42 is less likely to be cleared from the brain to the periphery in individuals in whom amyloid deposition is actively occurring[49]. In contrast, Aβ42/Aβ40 ratios are not affected in younger adults who have not yet started to experience Aβ42 aggregation.

Our initial results showing that slow breathing practice reduced plasma Aβ levels raise an important question: Might slow breathing during meditation reduce plasma Aβ levels? As a first step, we examined in younger adults whether one week of daily mindfulness meditation practice with or without slow breathing instruction would differentially affect plasma Aβ levels and plasma Aβ42/Aβ40 ratios compared with no intervention controls (primary outcomes measures). We also tested if the two types of meditation practices would affect plasma pTau-181/tau ratio, another biomarker for brain clearance, and emotional well-being (secondary outcome measures). We hypothesized that 1) mindfulness meditation with slow breathing (M+SB) would reduce plasma Aβ40 and Aβ42 levels whereas mindfulness meditation without slow breathing (M-SB) and no intervention would not; 2) none of the three groups would show changes in plasma Aβ42/40 ratio or plasma pTau-181/tau ratio since participants in this study are too young (18-35

years) to have brain Aβ and tau deposition; 3) both meditation conditions (M+SB and M-SB) would show greater improvement in emotional well-being compared with the no-intervention condition. Although it was not the focus of the study, we also tested the hypothesis that the M+SB condition would show greater episodic memory for positive items relative to the other conditions (pre-registered as other pre-specified outcome measures), as indicated in our preliminary findings[50].

Results

Heart rate oscillations during training vs. rest

We first examined whether M+SB participants breathed slowly during practice as they were instructed, which should lead to higher heart rate oscillation power in the low frequency range (0.04-0.15Hz or 7-25 sec) compared with their own baseline rest. Slow breathing was not anticipated in the M-SB and no-intervention conditions. As expected, we found a significant interaction of session type (baseline vs. training) and condition (M+SB, M-SB, no intervention), $F(1,87) = 28.98$, $p < 0.001$, $\eta_p^2 = .40$. M+SB participants increased LF power during practice compared with rest, $t(30) = 7.62$, $p < 0.01$, while such a difference was not observed in M-SB, $t(28) = 1.23$, $p = 0.231$, and no intervention, $t(29) = -1.46$, $p = 0.154$ (Fig. 2). We also examined condition differences in baroreflex frequency power (0.075-0.130Hz or 8-13 sec) and found a significant interaction of session type and condition, $F(1,87) = 33.31$, $p < 0.001$, $\eta_p^2 = .43$. Similar to LF power, M+SB participants increased baroreflex frequency power during practice compared with rest, $t(30) = 8.21$, $p < 0.01$. However, such a difference was not observed in M-SB, $t(28) = 0.90$, $p = 0.374$, and no intervention, $t(29) = -1.60$, $p = 0.121$ (Fig. 2). Other HRV parameters during practice, pre- and post-rest, and controlled breathing (e.g., LF, HF, RMSSD, heart rate) are reported in Supplementary Tables 1-3.

Figure 2. Comparisons of heart rate power spectral density in the three conditions.

Error bands represent the standard errors. Power spectral density for baseline rest is the average across three conditions.

Intervention effects on plasma Aβ42, Aβ40 and Aβ42/Aβ40 ratio (primary outcome measures)

There was a significant 2 (time: pre, post) by 3 (condition: M+SB, M-SB, no intervention) interaction for an aggregate score between Aβ42 and Aβ40 levels, $F(2, 75) = 6.21$, $p = 0.003$, $\eta_p^2 = 0.14$. The interaction was driven by M+SB reducing Aβ levels from pre- to post-intervention, $t(27) = -2.67$, $p = 0.013$, M-SB increasing Aβ levels, $t(23) = 2.53$, $p = 0.019$, and no-intervention showing no changes, $t(23) = -0.20$, $p = 0.847$. When we examined Aβ42 and

Aβ40 levels separately, there were also significant time-by-condition interactions for Aβ42, $F(2, 75) = 6.86$, $p = 0.002$, $\eta_p^2 = 0.16$, and for Aβ40, $F(2, 75) = 3.87$, $p = 0.025$, $\eta_p^2 = 0.09$ (Fig. 3a-3b). Aβ42 levels were decreased in M+SB, $t(27) = -2.10$, $p = 0.045$, increased in M-SB, $t(23) = 3.31$, $p = 0.003$, and showed no changes in no intervention, $t(25) = 0.09$, $p = 0.993$. Aβ40 levels were increased in M-SB, $t(23) = 2.47$, $p = 0.021$, and showed no changes in M+SB, $t(27) = -1.51$, $p = 0.142$ (with a decreasing trend), and no intervention, $t(25) = 0.38$, $p = 0.707$. As expected, we did not find a significant time-by-condition interaction for Aβ42/Aβ40 ratio, $F(2, 72) = 0.78$, $p = 0.460$, $\eta_p^2 = 0.021$. The means of all biomarkers for each condition and for each time point are reported in Table 1.

Figure 3.

b

Pre-to-post changes in plasma Aβ42 (a) and Aβ40 (b). *One week of daily mindfulness meditation with (red bars) and without (blue bars) baroreflex-frequency breathing had opposite effects on plasma Aβ levels.*

Table 1

plasma biomarker	M+SB		M-SB		no intervention		time	time x condition
	pre	*post*	*pre*	*post*	*pre*	*post*	*p*	*p*
Aβ42 & Aβ40 aggregate	0.02 (0.17)	-0.29 (0.16)	-0.38 (0.19)	-0.08 (0.17)	0.24 (0.18)	0.22 (0.16)	0.905	0.003*
Aβ42	8.83 (0.33)	8.34 (0.31)	8.05 (0.35)	8.78 (0.33)	9.31 (0.34)	9.33 (0.32)	0.524	0.002*
Aβ40	168.41 (6.71)	162.176 (5.97)	155.36 (7.25)	167.61 (6.45)	174.79 (6.97)	176.69 (6.19)	0.333	0.025*
Aβ42/Aβ40 ratio	0.05 (0.001)	0.05 (0.001)	0.05 (0.002)	0.05 (0.002)	0.05 (0.001)	0.05 (0.002)	0.596	0.460
pTau-181/tTau ratios	4.78 (0.37)	5.29 (0.36)	5.30 (0.38)	4.73 (0.37)	5.02 (0.38)	4.64 (0.37)	0.531	0.127
pTau-181	32.76 (4.19)	36.26 (4.34)	32.76 (4.19)	36.30 (4.66)	35.90 (4.12)	38.59 (4.57)	0.098	0.954
tTau	5.17 (0.56)	7.30 (0.71)	5.17 (0.56)	7.30 (0.71)	5.98 (0.55)	6.49 (0.70)	0.006*	0.163

Intervention effects on plasma pTau-181/tTau ratios (secondary outcome measures)

As hypothesized, there was no significant time-by-condition interaction for pTau-181/tTau ratio, $F(2, 68) = 2.13$, $p = 0.127$, $\eta_\mathrm{p}^2 = 0.059$ (the means are reported in Table 1) . Also there was no significant time-by-condition interaction for pTau-181, $F(2, 80) = 0.05$, $p = 0.954$, $\eta_\mathrm{p}^2 = 0.001$, or for tTau, $F(2, 71) = 1.86$, $p = 0.163$, $\eta_\mathrm{p}^2 = 0.050$.

Intervention effects on emotional well-being (secondary outcome measures)

Since there were significant baseline differences in several emotion measures between the conditions (i.e., mood, depression and mindfulness; the means are reported in Supplementary Table 4), we performed univariate analyses comparing post-intervention scores of the three conditions while controlling for pre-intervention scores of each emotion outcome variable. However, there were no significant condition differences in any of these measures at post intervention (Supplementary Table 4), suggesting that neither meditation intervention had a significant impact on participants' subjective mood, stress, anxiety, depression or mindfulness. Two-way ANOVA results are also reported in the "Intervention effects on emotional well-being" section of Supplementary Information.

Intervention effects on emotional memory (pre-registered as other pre-specified outcome measure)

Since our preliminary findings suggest that a slow-paced breathing intervention influences positive emotional memory[50], we first calculated a summary positive emotional memory bias score with false recognition and recall contributing equally to the formula (see the Analyses section in Methods for more details). There was no significant condition difference in positive emotional memory bias score, $F(2, 80) = 0.424$, $p = 0.656$, $\eta_\mathrm{p}^2 = 0.010$. We also examined condition differences in recall and recognition performances separately, but no

significant results were found (see "Intervention effects on emotional memory" in Supplementary Information).

Additional analyses on the relationships between HRV and plasma biomarkers

We conducted exploratory correlation analyses between HRV during practice and pre-to-post changes in plasma biomarkers (Supplementary Table 5) and between pre-to-post changes in HRV and those in plasma biomarkers (Supplementary Table 6), but no significant correlations were found.

Discussion

This study examined whether a short course of one week of practicing mindfulness meditation with or without slow breathing around the baroreflex frequency would differentially affect plasma biomarkers for AD and emotional well-being. We found support for our first hypothesis that meditative practice incorporating slow breathing would reduce plasma Aβ levels whereas the other conditions would not. We also found support for our second hypothesis that plasma Aβ42/40 ratio and plasma pTau-181/tau ratio would not be affected by any of the interventions. We did not find support for our third hypothesis that both meditation conditions would improve emotional well-being relative to a no intervention control.

As discussed earlier, slow breathing may affect Aβ levels by modulating Aβ production. Our hypothesis is that slow breathing around the baroreflex frequency drives the α-secretase APP nonamyloidogenic pathway and suppresses the β-secretase amyloidogenic pathway, leading to a reduction of Aβ production. This may explain Aβ reduction observed in the M+SB condition. Aβ increase in the M-SB condition was unexpected. One possible explanation is that focusing attention on body sensations might have required cognitive effort in these novice meditators, which in turn may have led to elevated arousal/noradrenaline levels leading to increased plasma

Aβ. While both meditation groups were instructed to focus their attention on the sensations around the belly, M+SB participants might have been able to counteract high levels of arousal by parasympathetic (vagus) stimulation via the baroreflex frequency breathing that was encouraged. In more naturalistic common mindfulness meditation breath-focused practice instruction includes the explicit encouragement to allow the body to relax and/or taking a few deep breaths at the outset to encourage relaxation. The fact that these instructions were not included may also contribute to the effects seen in the M-SB group as the instructions were focused more purely on the attentional aspect without emphasizing the relaxation aspect of practice.

Another element of this study worth highlighting is that changes in plasma Aβ levels were observed after a one-week intervention, which was much shorter than the 4-week slow breathing intervention in our previous study[32]. Our results indicated that the effects of baroreflex-frequency breathing on plasma Aβ can occur relatively quickly, which is consistent with prior findings of overnight changes in plasma Aβ levels[51] or even within hours[51,52].

None of the three conditions affected plasma Aβ42/40 ratios and plasma pTau-181/tau ratio. As discussed earlier, plasma Aβ42 levels decrease around the time of an AD diagnosis[33], resulting in a reduction in plasma Aβ42/Aβ40 ratios. Aβ42 is more likely than Aβ40 to form aggregates in the brain[48], and less likely to be cleared from the brain to the periphery in those whom amyloid deposition is actively occurring[49]. Consistent with this idea, our younger participants who presumably have not started to experience Aβ42 aggregation did not show changes in plasma Aβ42/Aβ40 ratios. The result was consistent with our prior findings that baroreflex-frequency breathing increased plasma Aβ42/Aβ40 ratios in older adults but not in younger adults[32].

In contrast with physiological changes, the psychological benefits of meditation may take time to manifest. We failed to observe improvements in emotional well-being, including mood, stress, anxiety, depression and mindfulness. We also did not observe condition differences in positivity bias in episodic memory. The lack of behavioral improvements may partially be due to limitations in the study design. It is possible that the duration of intervention was too short, as some prior findings suggest that longer practice was associated with greater behavioral benefits[53–55]. Another possibility is that participants needed more guidance to navigate through the initial difficulty in learning meditation. Future studies should incorporate these considerations.

To our knowledge, our initial findings on the effects of slow breathing intervention on plasma Aβ levels[32] are the first from a randomized clinical trial to show that a behavioral intervention can reduce Aβ levels (measured via plasma, CSF or PET imaging) in healthy adults relative to a control group. The current study further sheds light on how slow breathing in the context of mindfulness meditation could help reduce plasma Aβ levels. In the current and previous studies, our outcome measure was plasma Aβ. Thus, a critical next step is to investigate what happens to Aβ42 levels in the brain. Plasma Aβ reflects both peripheral and brain sources of Aβ, and baroreflex-frequency breathing may or may not have similar effects on Aβ in the brain as in the periphery. Future studies should examine whether this intervention has similar effects on Aβ levels in the periphery (blood) and in the brain (CSF). It is also important to extend this study to middle-aged and older adults who may be starting or have already started to aggregate Aβ42 in the brain.

Future studies using fMRI would be informative for understanding common and separate neural mechanisms underlying M+SB vs. M-SB. A meta-analysis[56] suggests that focused

attention meditation (which is similar to the one used in this study) involves altering the dynamics of the default mode network (DMN), the salience network and the executive control network. Dysfunction of the same networks with an additional involvement of the locus coeruleus (LC) have been implicated in age-related attentional deficits and distractibility[57]. The LC is the brain's primary source of noradrenaline and involved in arousal, attention, memory, respiration and the neuropathological progression of AD[58–63]. We hypothesize that phasic stimulation of LC via the M+SB intervention may enhance the functional organization of the LC-networks, which may in turn lead to behavioral improvements, such as reduced distractibility and enhanced cognitive performance. On the other hand, the M-SB intervention may affect these networks differently.

From a practical perspective, these findings contribute to a body of evidence suggesting that the benefits of meditative practice may be related to slowing of the breath[14–16,64]. Given this, studies assessing the relative benefit of arriving at slow breathing rates without intentional effort through the relaxation that occurs from engaging in practice regularly over time vs. as a result of purposeful slowing of the breath may be justified. Mainstream schools of mindfulness meditation practice often do not instruct students to engage in slow breathing out of a sense that controlling the breath might lead away from the experience of equanimity and acceptance - accepting the breath exactly as it naturally occurs. More rigorous exploration of the pros and cons of including slow breath instructions in meditative interventions could help identify optimal ways to teach meditation to different populations depending on their baseline characteristics and desired outcomes.

This study demonstrated that physiological aspects of meditation can influence plasma biomarkers associated with AD. Our findings also highlight that this area of research deserves

more attention and further investigation. Future studies should examine the underlying mechanisms of the effects of baroreflex-frequency breathing on Aβ in the brain, which can potentially help prevent or delay the progression of AD and may contribute to the understanding of AD pathology, in particular linking Aβ production and the cholinergic system[65].

Acknowledgments

This study was supported by Epstein Breakthrough Alzheimer's Research Fund (PI: Mather, co-PI: Choupan) and by R01AG080652 (PI: Mather).

Contributions

M.M. and K.N. conceptualized and designed the study with the input from R.B.C. K.N. directed the research team and analyzed the data. Data collection was performed by P.C, H.J.L, K.N and S.S. J.M., H.Y. and C.C. helped with the initial setup of the study. J.M. and H.Y. provided technical assistance with data acquisition and analyses. With the input from M.M. and K.N., N.M built a customized app and contributed to data management. L.S. performed blood assays under the supervision of E.H. K.N drafted the initial manuscript. M.M. and all other authors reviewed and edited the draft and approved the final manuscript.

Competing Interests statement

The authors declare no competing interests.

Methods

Pilot studies

Before running the actual study, we conducted three pilot experiments to identify two types of mindfulness meditation practices: one incorporating slow breathing and the other without it. Previous research found that "anapanasati" (mindfulness of breath) practice in long term Vipassana meditators in the Goenka tradition (with a nostril focus) did not increase LF-HRV compared with rest or random thinking[26], suggesting that mindfulness of breath practice may not necessarily elicit slow breathing. We thought that this might have to do with the location of the focus of attention. Participants in this study focused on the nostrils where the passage of air can make it harder to detect minute sensation, which might have quieted their breathing (shallow breathing rather than slow breathing). In contrast, we thought that the more typical breath-focused mindfulness that directs attention to the belly would encourage slow breathing. We pilot tested this comparison (belly-focus, nostril-focus or control; see Supplementary Table 7 for the meditation scripts) with 6 participants doing the 20-minute practice twice a day for 7 days while recording their pulse (two people in each condition). The control group was instructed to do whatever they wanted as long as their activity did not involve motion (e.g., use your phone or computer, read a book). To our surprise, we found that neither meditation condition increased LF-HRV much relative to control (Supplementary Figure 1a), indicating that neither elicited slowed breathing (we had expected the belly-focus condition to slow down breathing). In the second pilot study, we tried modifying the instructions to make breathing differ more between the two meditation conditions with another 6 people (this time just practicing once for 20 minutes). As shown in Supplementary Table 8, we attempted to encourage the belly-focus group to breathe slowly and guide the nostril-focus group to breathe quietly without explicitly instructing them to change their breathing rate. However, we found that neither group increased

LF-HRV, indicating no changes in breathing rate, relative to their own resting state (Supplementary Figure 1b). In the third pilot study, we provided explicit instructions to breathe slowly to one meditation group but not the other (Supplementary Table 9). Since we thought that it is also important to keep the two meditation conditions the same except for the presence or absence of slow breathing, we decided to give the same meditation instructions (i.e., belly-focus) to both groups. Three participants performed both types of meditations for 10 min each in a random order as well as a 5-min rest. The belly-focus mindfulness meditation with the slow breathing instructions increased LF-HRV relative to rest, which was not observed in the belly-focus meditation without slow breathing instructions (Supplementary Figure 1c). The three pilot experiments informed us that slow breathing does not naturally occur in novice meditators during mindful attention to breath, and therefore we needed to provide explicit instructions to incorporate slow breathing during meditation. The final design of this study is described in the "Overview of 1-week Protocol Schedule" section below.

Participants

We recruited 94 participants from online advertisements (e.g., USC Healthy Minds Research Volunteer Registry, USC Slack student groups, Volunteer Match), flyers or personal referrals. Participants provided informed consent approved by the USC Institutional Review Board. Participants were screened to ensure that they speak English fluently, are between age 18 and 35, agree to provide blood samples and devote 40 minutes daily for an assigned intervention, and did not currently practice any relaxation, biofeedback, or breathing technique (e.g., meditation) for more than an hour a week. We excluded people with abnormal cardiac rhythms, dyspnea, or heart disease. Two people dropped out of the study before the intervention began (one participant fainted right after blood draw and another participant was no longer interested in participating in the study). Three people withdrew from the study after the intervention began

since they could not commit to complete home practice as they originally thought. The

remaining 89 participants were included in our analyses (Fig. 4). Age, sex and education were

similar in the three conditions (Table 2).

Figure 4. CONSORT Flow Diagram.

Number of participants who enrolled, were allocated to conditions and included in each

analysis.

Table 2

	Age		Years of education		Sex	
	Mean (SD)	*Range*	*Mean (SD)*	*Range*	*Female*	*Male*
Belly (n=27)	25.07 (SD=5.16)	19-35	15.88 (SD=1.86)	12-19	21	6
Belly + SB (n=32)	26.25 (SD=5.29)	18-35	16.19 (SD=1.93)	12-20	26	6
No Intervention (n=30)	26.20 (SD=4.82)	18-35	16.47 (SD=2.56)	13-23	25	5

Overview of 1-week Protocol Schedule

Participants visited the lab twice, once before and once after the one-week intervention. During both visits, participants completed a blood draw, questionnaires (see the *Questionnaires* section for more detail) and a resting pulse measure for 5 minutes. In addition, participants performed 5 minutes of paced breathing at 15 breaths per minute by following a visual pacer, which allowed us to measure HRV while controlling for breathing pace. The customized application randomly assigned participants to one of the three conditions (belly-focus concentration meditation, belly-focus concentration meditation with slow breathing, no-intervention control), stratified by participant sex with a block size of three. Between the two lab visits, participants were instructed to engage in the assigned practice for 20 minutes, twice a day (i.e., a total of 40 minutes/day). The first 20-minute practice session was performed during the first visit under the experimenter's supervision. The rest of the practice was conducted at home.

Mindfulness meditation without slow breathing condition (M-SB)

Participants wore an ear sensor to measure their pulse. The sensor cable was connected to a USB module plugged into a USB port on the training laptop computer. Participants viewed the instructions on the customized app while the emWave pro software[66] ran in the background, which was not visible to the participants. The app showed instructions, "You will be asked to sit quietly to meditate for 20 minutes while your heart rate is recorded. During this time, you will

listen to a guided meditation to help you focus on the sensations around the belly. Please remember that it is normal for the mind to wander. When this happens, gently bring your attention back to your belly." Once participants pressed start, the recording began. Participants were asked to gently close their eyes and focus their attention on the sensations around the belly. The entire guided meditation script can be found in Supplementary Table 10.

Mindfulness meditation with slow breathing condition (M+SB)

Participants were given the same devices and instructions as in the belly-focus meditation condition with one additional instruction to breathe slowly during the entire meditation session. Once participants pressed start, the recording began and asked participants to gently close their eyes. Participants were guided to focus their attention on the sensations around the belly while breathing slowly at around 10 seconds per breath. The guiding voice said, "Take long slow breaths as I guide you. Inhale for a count to 5 and exhale for a count to 5. Breathe slowly and gently at this pace during the entire meditation exercise. I'll count with you for the first few breaths. Then you can count on your own. Inhale, 2, 3, 4, 5, exhale 2, 3, 4, 5. Inhale, 2, 3, 4, 5, exhale 2, 3, 4, 5. Continue breathing this way on your own." The entire guided meditation for this condition can be found in Supplementary Table 10.

No-intervention control condition

Participants were given the same devices as in the two other conditions. The app instructed, "You will be asked to sit quietly for 20 minutes while your heart rate is recorded. Please feel free to do whatever you would like to do (e.g., use your phone or computer, read a book, watch TV, listen to music) as long as your activity does not involve head motion." Once participants pressed start, the recording began as participants started the activity of their choice.

Coaching

During the initial 20-minute practice session in the lab, the experimenter monitored the participant's real time heart rate data to ensure that their breathing patterns aligned with their conditions (i.e., M+SB participants were instructed to breathe slowly around 10s/breath reflected by large heart rate oscillations whereas M-SB participants were supposed to breathe naturally reflected by small heart rate oscillations). Four participants in the M+SB condition failed to breathe slowly. Two participants in the M-SB condition failed to breathe naturally (they breathed slowly). We stopped their sessions before reaching the half-way point (i.e., 10 minutes), instructed them to breathe according to their condition and restarted their 20-min session. Since this additional coaching may have disrupted their natural physiological state during meditation, we repeated all the data analyses reported in the results section excluding these six participants. However, the results remain the same. The time-by-condition interactions for Aβ42 and Aβ40 remained significant. The rest of the results were non-significant.

Blood collection procedure

The blood samples were collected via antecubital venipuncture. Blood collection time of the day remained the same for both visits. A phlebotomist drew 10 ml of blood from each participant's arm into a K2 EDTA tube. To separate plasma from red blood cells, the whole blood from the K2 EDTA tubes was centrifuged at the speed of 1500 RPM for 15 min at room temperature (15°C). Plasma was aliquoted in cryovials and stored at −80 °C. The frozen plasma samples were transferred and assayed at University of California, Irvine for Aβ42, Aβ40, tTau, and pTau-181.

Questionnaires

Participants completed a demographic questionnaire during their first visit. At pre- and post-intervention lab visits, they completed the profile of mood states[67], the sort-form version of depression anxiety stress scales[68] and the 15-item version of the five facet mindfulness

questionnaire[69,70]. We used the 40-item version of POMS. Participants indicated how much each item reflected how they felt at the moment using a scale from 1 (not at all) to 5 (extremely). Total mood disturbance was calculated by subtracting positive-item totals from negative-item totals. A constant value (i.e., 100) was added to the total mood disturbance to eliminate negative scores. Higher scores indicate greater negative affect. The DASS-21 consisted of 21 items with three subscales: depression, anxiety, and stress. Each subscale comprises seven items, which reflect a symptom of depression, anxiety, and stress. Participants reported how much each statement applied to them in the past week using a 4-point scale ranging from 0 (did not apply to me at all) to 3 (applied to me very much or most of the time). The total points for each category were summed up and multiplied by 2. Higher scores indicate more frequent symptomatology. The FFMQ consisted of five subscales: observing, describing, acting with awareness, nonjudging of inner experience and nonreacting of inner experience. Participants responded to each item using a 5-point scale ranging from 1 (never/rarely true) to 5 (very often/always true). We reverse-scored negatively worded items and summed items to create subscale and total scores. Since it is recommended that researchers should exclude the observing facet score from comparisons of total scale/subscale scores before and after mindfulness interventions[70], we excluded the observing score from our analyses.

Emotional memory task

We measured episodic memory as a pre-specified outcome measure (not primary or secondary) since we were interested in the effects of the interventions on emotional memory. Before each 20-minute practice session, the customized application showed participants six images, two from each valence category (positive, negative, neutral) from the Nencki Affective Picture System (NAPS)[71] using jsPsych[72]. They were asked to rate each picture on a scale of 1-9 (1 = very negative to 9 = very positive, with 5 = neutral). At the post-intervention visit, they were

given surprise recall and recognition memory tests on those images. First, participants were

given a free recall test where they were asked to describe in detail as many images as they could

that they saw in the past week. There was no time limit imposed for the free recall. Next,

participants were given a recognition test where they viewed the 84 old images and 42

previously new images. For 16 people who did not encode all pictures since they missed some

practice sessions, we adjusted the total number of pictures when calculated their memory scores

(e.g., if participants missed 2 practices, which means they missed to encode 12 pictures, we

subtracted 12 from 84 old images).

Analyses

For heart rate variability analyses, we conducted a 2 (session type: baseline vs. training) x

3 (condition: M+SB, M-SB, no intervention) ANOVA.We performed 2 (time: pre-, post-

intervention) x 3 (condition: M+SB, M-SB, no intervention) ANOVAs to test the intervention

effect on all outcome measures unless otherwise mentioned. Post-hoc paired samples t-tests were

conducted to compare pre- and post-intervention values for each condition.

Heart rate variability during home practice and seated rest

The pulse data recorded by emWave pro software and sensor unit were saved in a

database file on the laptop. The database file was also transferred to a remote server via internet

connection by custom software. Interbeat interval (IBI) data were exported from the database file

for HRV analysis. We used Kubios HRV Premium 3.1[73] to compute autoregressive spectral

power, the standard heart rate variability measures of low frequency HRV (LF-HRV, 0.04-0.15

Hz), high frequency HRV (HF-HRV, 0.15-0.4 Hz) and root mean squared successive difference

(RMSSD) and mean heart rate for each practice session and for 5-minute rest sessions during

pre- and post-intervention lab visits. We averaged the autoregressive total spectral power from

all practice sessions for each participant. We excluded data with extreme values of RMSSD (>

200), which were 18 training sessions and 1 post-intervention resting session. For each participant, we extracted the summed power within 0.058-0.130Hz (corresponding 8-17 sec; LF power) and 0.075-0.130Hz (corresponding with 8-13 sec; baroreflex frequency power) to obtain a measure of heart rate oscillatory activity during practice. Before conducting statistical analyses, we log transformed the LF and HF power values.

Plasma assay procedure

Plasma samples were analyzed using the automated Simoa SR-X analyzer with the commercially available Simoa Human Neurology 3-Plex A assay kit (Quanterix, Billerica, MA, USA) for Aβ42, Aβ40, and tTau. Plasma concentrations of pTau-181 were measured using the automated Simoa HD-X analyzer and the Simoa pTau-181 Advantage V2 kit (Quanterix, Billerica, MA, USA). Analyses were performed in duplicates (mean % coefficient of variation [%CV]: Aβ42: 6.33, Aβ40: 4.55, tTau: 8.81, pTau-181: 6.01) using a 1:4 dilution protocol according to the manufacturer's instructions. Prior to analysis, plasma samples were thawed at room temperature for 1 h and centrifuged at 10,000×g for 5 min to prevent transfer of debris. All assays were conducted by the same operator with the same respective instrument. As in our previous study[32], we defined outliers who on a box-and-whisker plot were above Q3 + 3 * the interquartile range on each of plasma measures (Aβ42, Aβ40, Aβ42/Aβ40 ratio, pTau/tTau ratio, pTau-181, tTau) for pre- and post-intervention separately. This resulted in excluding outliers for pre-intervention Aβ42/Aβ40 ratio (N=3), post-intervention Aβ42/Aβ40 ratio (N=1), pre-intervention pTau (N=1), pre-intervention tTau ratio (N=4), and post-intervention tTau ratio (N=2), pre-intervention pTau/tTau ratio (N=4), and post-intervention pTau/tTau ratio (N=3).

We examined the relationships between pre-to-post changes in plasma biomarkers and HRV during practice. We also examined the correlations between changes in plasma biomarkers

and changes in HRV. For these correlation analyses, a significant threshold was set at false discovery rate (FDR) $p < 0.05$.

Emotional well-being

We defined outliers for each emotion measure if their pre-intervention or post-intervention values were greater than the third quartile plus three times of interquartile range or lower than the first quartile minus three times of the interquartile range based on the boxplot rule of SPSS. This resulted in excluding outliers for pre-intervention POMS (N=4), post-intervention depression (N=2), and pre-intervention FFMQ (N=1).

Emotional memory

Following the method used in our previous study[50], we created a summary positive emotional memory bias score with false recognition and recall contributing equally to the formula. The *Z* scores for positive and negative false alarms and correct recall counts were calculated across participants. This means that the average false alarm rates and correct recall counts for positive and negative images were set to zero and variability was normalized such that scores of ± 1 reflected a bias one standard deviation from the mean for that type of item. We computed positive emotional memory bias score with the following formula: (Z FalseAlarmPositive—Z FalseAlarmNegative) + (Z CorrectRecallPositive—Z CorrectRecallNegative). We performed a one-way ANOVA to assess condition differences on the positive emotional bias score. In addition, we conducted separate analyses for recall and recognition performance (see Supplementary Information).

References

1. Lazar, S. W. *et al.* Meditation experience is associated with increased cortical thickness. *Neuroreport* **16**, 1893–1897 (2005).

2. Pagnoni, G. & Cekic, M. Age effects on gray matter volume and attentional performance in Zen meditation. *Neurobiol Aging* **28**, 1623–1627 (2007).

3. Luders, E., Clark, K., Narr, K. L. & Toga, A. W. Enhanced brain connectivity in long-term meditation practitioners. *Neuroimage* **57**, 1308–1316 (2011).

4. Luders, E. Exploring age-related brain degeneration in meditation practitioners. *Ann N Y Acad Sci* **1307**, 82–88 (2014).

5. Luders, E., Cherbuin, N. & Gaser, C. Estimating brain age using high-resolution pattern recognition: Younger brains in long-term meditation practitioners. *Neuroimage* **134**, 508–513 (2016).

6. Luders, E., Cherbuin, N. & Kurth, F. Forever Young(er): potential age-defying effects of long-term meditation on gray matter atrophy. *Front Psychol* **5**, 1551 (2014).

7. Epel, E. S. *et al.* Meditation and vacation effects have an impact on disease-associated molecular phenotypes. *Transl Psychiatry* **6**, e880 (2016).

8. Innes, K. E. & Selfe, T. K. Meditation as a therapeutic intervention for adults at risk for Alzheimer's disease - potential benefits and underlying mechanisms. *Front Psychiatry* **5**, 40 (2014).

9. Lutz, A. *et al.* The protective effect of mindfulness and compassion meditation practices on ageing: Hypotheses, models and experimental implementation. *Ageing Res Rev* **72**, 101495 (2021).

10. National Academies of Sciences Engineering and Medicine, Division of Behavioral and

Social Sciences and Education, Board on Behavioral Cognitive and Sensory Sciences & Committee on the Decadal Survey of Behavioral and Social Science Research on Alzheimer's Disease and Alzheimer's Disease-Related Dementias. *Reducing the Impact of Dementia in America: A Decadal Survey of the Behavioral and Social Sciences*. (2022).

11. Klimecki, O. *et al.* The impact of meditation on healthy ageing - the current state of knowledge and a roadmap to future directions. *Curr Opin Psychol* **28**, 223–228 (2019).

12. Chételat, G. *et al.* Why could meditation practice help promote mental health and well-being in aging? *Alzheimers Res Ther* **10**, 57 (2018).

13. Crosswell, A. D. *et al.* Deep rest: An integrative model of how contemplative practices combat stress and enhance the body's restorative capacity. *Psychol Rev* **131**, 247–270 (2024).

14. Karunarathne, L. J. U., Amarasiri, W. A. D. L. & Fernando, A. D. A. Respiratory function in healthy long-term meditators: A cross-sectional comparative study. *Heliyon* **9**, e18585 (2023).

15. Karunarathne, L. J. U., Amarasiri, W. A. D. L. & Fernando, A. D. A. Respiratory function in healthy long-term meditators: a systematic review. *Syst Rev* **13**, 1 (2024).

16. Wielgosz, J., Schuyler, B. S., Lutz, A. & Davidson, R. J. Long-term mindfulness training is associated with reliable differences in resting respiration rate. *Sci Rep* **6**, 27533 (2016).

17. Lehrer, P. M. & Gevirtz, R. Heart rate variability biofeedback: how and why does it work? *Front Psychol* **5**, 756 (2014).

18. Nashiro, K. *et al.* Increasing coordination and responsivity of emotion-related brain regions with a heart rate variability biofeedback randomized trial. *Cogn. Affect. Behav. Neurosci.* **23**, 66–83 (2023).

19. Burlacu, A., Brinza, C., Popa, I. V., Covic, A. & Floria, M. Influencing Cardiovascular Outcomes through Heart Rate Variability Modulation: A Systematic Review. *Diagnostics (Basel)* **11**, (2021).

20. Bernardi, L. *et al.* Effect of rosary prayer and yoga mantras on autonomic cardiovascular rhythms: comparative study. *BMJ* **323**, 1446–1449 (2001).

21. Lehrer, P., Sasaki, Y. & Saito, Y. Zazen and cardiac variability. *Psychosom Med* **61**, 812–821 (1999).

22. Peng, C.-K. *et al.* Heart rate dynamics during three forms of meditation. *Int J Cardiol* **95**, 19–27 (2004).

23. Phongsuphap, S., Pongsupap, Y., Chandanamattha, P. & Lursinsap, C. Changes in heart rate variability during concentration meditation. *Int J Cardiol* **130**, 481–484 (2008).

24. Peng, C. K. *et al.* Exaggerated heart rate oscillations during two meditation techniques. *Int J Cardiol* **70**, 101–107 (1999).

25. Wei, G.-X. *et al.* Tai Chi Chuan modulates heart rate variability during abdominal breathing in elderly adults. *Psych J* **5**, 69–77 (2016).

26. Delgado-Pastor, L. C., Perakakis, P., Subramanya, P., Telles, S. & Vila, J. Mindfulness (Vipassana) meditation: effects on P3b event-related potential and heart rate variability. *Int J Psychophysiol* **90**, 207–214 (2013).

27. Kodituwakku, S. *et al.* Point process time-frequency analysis of dynamic respiratory patterns during meditation practice. *Med Biol Eng Comput* **50**, 261–275 (2012).

28. Sukhsohale, N. D. & Phatak, M. S. Effect of short-term and long-term Brahmakumaris Raja Yoga meditation on physiological variables. *Indian J Physiol Pharmacol* **56**, 388–392 (2012).

29. Wallace, R. K. & Benson, H. The physiology of meditation. *Scientific American* **226**, 84–91 (1972).

30. Telles, S., Nagarathna, R. & Nagendra, H. R. Autonomic changes during 'OM' meditation. *Indian J Physiol Pharmacol* **39**, 418–420 (1995).

31. Telles, S. & Desiraju, T. Autonomic changes in Brahmakumaris Raja yoga meditation. *Int J Psychophysiol* **15**, 147–152 (1993).

32. Min, J. *et al.* Modulating heart rate oscillation affects plasma amyloid beta and tau levels in younger and older adults. *Sci. Rep.* **13**, 3967 (2023).

33. Song, F. *et al.* Meta-analysis of plasma amyloid-β levels in Alzheimer's disease. *J. Alzheimers. Dis.* **26**, 365–375 (2011).

34. Chen, G.-F. *et al.* Amyloid beta: structure, biology and structure-based therapeutic development. *Acta Pharmacol Sin* **38**, 1205–1235 (2017).

35. Chen, Y. *et al.* α(2A) adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction. *Proc Natl Acad Sci U S A* **111**, 17296–17301 (2014).

36. Ni, Y. *et al.* Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. *Nat Med* **12**, 1390–1396 (2006).

37. Hardy, J. & Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* **297**, 353–356 (2002).

38. Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Mol Med* **8**, 595–608 (2016).

39. Luo, J. *et al.* Accelerated longitudinal changes and ordering of Alzheimer disease biomarkers across the adult lifespan. *Brain* **145**, 4459–4473 (2022).

40. Scheuner, D. *et al.* Secreted amyloid beta-protein similar to that in the senile plaques of

Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. *Nat Med* **2**, 864–870 (1996).

41. Head, E. *et al.* Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. *J Alzheimers Dis* **23**, 399–409 (2011).

42. Coppus, A. M. W. *et al.* Plasma β amyloid and the risk of Alzheimer's disease in Down syndrome. *Neurobiol Aging* **33**, 1988–1994 (2012).

43. Tokuda, T. *et al.* Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down's syndrome. *Ann Neurol* **41**, 271–273 (1997).

44. Ertekin-Taner, N. *et al.* Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. *Neurology* **70**, 596–606 (2008).

45. Ertekin-Taner, N. *et al.* Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. *Science* **290**, 2303–2304 (2000).

46. Schindler, S. E. *et al.* High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. *Neurology* **93**, e1647–e1659 (2019).

47. West, T. *et al.* A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis. *Mol Neurodegener* **16**, 30 (2021).

48. Masters, C. L. & Selkoe, D. J. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. *Cold Spring Harb Perspect Med* **2**, a006262 (2012).

49. Roberts, K. F. *et al.* Amyloid-β efflux from the central nervous system into the plasma. *Ann Neurol* **76**, 837–844 (2014).

50. Cho, C. *et al.* Changes in Medial Prefrontal Cortex Mediate Effects of Heart Rate Variability Biofeedback on Positive Emotional Memory Biases. *Appl. Psychophysiol.*

Biofeedback **48**, 135–147 (2023).

51. Lucey, B. P. *et al.* Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics. *Ann Neurol* **83**, 197–204 (2018).

52. Ovod, V. *et al.* Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. *Alzheimers Dement* **13**, 841–849 (2017).

53. Basso, J. C., McHale, A., Ende, V., Oberlin, D. J. & Suzuki, W. A. Brief, daily meditation enhances attention, memory, mood, and emotional regulation in non-experienced meditators. *Behav Brain Res* **356**, 208–220 (2019).

54. Fredrickson, B. L. *et al.* Positive Emotion Correlates of Meditation Practice: A Comparison of Mindfulness Meditation and Loving-kindness Meditation. *Mindfulness (N Y)* **8**, 1623–1633 (2017).

55. Lacaille, J. *et al.* Daily Mindful Responding Mediates the Effect of Meditation Practice on Stress and Mood: The Role of Practice Duration and Adherence. *J Clin Psychol* **74**, 109–122 (2018).

56. Ganesan, S. *et al.* Focused attention meditation in healthy adults: A systematic review and meta-analysis of cross-sectional functional MRI studies. *Neurosci Biobehav Rev* **141**, 104846 (2022).

57. Lee, T.-H., Kim, S. H., Katz, B. & Mather, M. The Decline in Intrinsic Connectivity Between the Salience Network and Locus Coeruleus in Older Adults: Implications for Distractibility. *Front Aging Neurosci* **12**, 2 (2020).

58. Mather, M. & Harley, C. W. The Locus Coeruleus: Essential for Maintaining Cognitive Function and the Aging Brain. *Trends Cogn Sci* **20**, 214–226 (2016).

59. Dahl, M. J., Mather, M. & Werkle-Bergner, M. Noradrenergic modulation of rhythmic neural activity shapes selective attention. *Trends Cogn Sci* **26**, 38–52 (2022).

60. Dahl, M. J., Mather, M., Sander, M. C. & Werkle-Bergner, M. Noradrenergic Responsiveness Supports Selective Attention across the Adult Lifespan. *J Neurosci* **40**, 4372–4390 (2020).

61. Dahl, M. J. *et al.* Rostral locus coeruleus integrity is associated with better memory performance in older adults. *Nat Hum Behav* **3**, 1203–1214 (2019).

62. Gargaglioni, L. H., Hartzler, L. K. & Putnam, R. W. The locus coeruleus and central chemosensitivity. *Respir Physiol Neurobiol* **173**, 264–273 (2010).

63. Yackle, K. *et al.* Breathing control center neurons that promote arousal in mice. *Science* **355**, 1411–1415 (2017).

64. Kral, T. R. A. *et al.* Slower respiration rate is associated with higher self-reported well-being after wellness training. *Sci Rep* **13**, 15953 (2023).

65. Majdi, A. *et al.* Amyloid-β, tau, and the cholinergic system in Alzheimer's disease: seeking direction in a tangle of clues. *Rev Neurosci* **31**, 391–413 (2020).

66. Heartmath. *EmWave Pro Plus*. https://store.heartmath.com/emwave-pro-plus/ (2016).

67. Grove, J. R. & Prapavessis, H. Preliminary evidence for the reliability and validity of an abbreviated Profile of Mood States. *Int. J. Sport Psychol.* **23**, 93–109.

68. Lovibond, P. F. & Lovibond, S. H. The structure of negative emotional states: comparison of the Depression Anxiety Stress Scales (DASS) with the Beck Depression and Anxiety Inventories. *Behav. Res. Ther.* **33**, 335–343 (1995).

69. Baer, R. A. & Carmody, J. Weekly change in mindfulness and perceived stress in a mindfulness-based stress reduction program. *Journal of clinical* (2012).

70. Gu, J. *et al.* Examining the factor structure of the 39-item and 15-item versions of the Five Facet Mindfulness Questionnaire before and after mindfulness-based cognitive therapy for people with recurrent depression. *Psychol Assess* **28**, 791–802 (2016).

71. Marchewka, A., Zurawski, Ł., Jednoróg, K. & Grabowska, A. The Nencki Affective Picture System (NAPS): introduction to a novel, standardized, wide-range, high-quality, realistic picture database. *Behav Res Methods* **46**, 596–610 (2014).

72. de Leeuw, J. R., Gilbert, R. A. & Luchterhandt, B. JsPsych: Enabling an open-source collaborative ecosystem of behavioral experiments. *J. Open Source Softw.* **8**, 5351 (2023).

73. Tarvainen, M. P., Niskanen, J.-P., Lipponen, J. A., Ranta-Aho, P. O. & Karjalainen, P. A. Kubios HRV--heart rate variability analysis software. *Comput Methods Programs Biomed* **113**, 210–220 (2014).